Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· November 24, 2025

Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals

View original at globenewswire.com
Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals Nanox’s HealthOST and HeathVCF recommended for use in UK National Health Service hospitals for a three-year period as the use of AI solutions in bone disease…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • NICE has recognized the potential of these tools through the Early Value Assessment, enabling us to generate the evidence needed to bring earlier detection to many more patients

    80% confidence
  • AI technologies can help healthcare professionals spot VFFs on X-ray images and CT scans involving the spine, that are done for unrelated conditions (opportunistic detection). This could help identify more people with a vertebral fragility fracture who need treatment to improve their quality of life and reduce the risk of future fractures.

    80% confidence
  • Nanox.AI's bone solutions represent a major step forward in transforming how we detect vertebral fragility fractures and intervene earlier in osteoporosis. The ADOPT trial has shown the impact of proactive identification, and these AI tools can help bring that approach into routine NHS care.

    80% confidence
  • Inclusion in this Early Value Assessment by NICE provides clear initial validation of the benefit that our AI bone solutions can provide in detection of vertebral fragility fractures, something which many solutions providers have yet to demonstrate. Our inclusion reflects that Nanox.AI delivers clinically validated, real-world results, not just theoretical concepts.

    80% confidence
  • By detecting low bone mineral density early—before symptoms appear—Nanox.AI solutions can be truly life-changing for patients who might otherwise remain undiagnosed

    80% confidence
  • Two of the five bone solutions recommended by NICE are from Nanox AI, enabling the company to build a footprint in UK hospitals

    80% confidence
  • HealthOST and HealthVCF analyze existing CT scans and require no additional imaging, introduce no extra radiation exposure and impose no added burden on the patient, positioning them as highly cost-effective methods to help identify risk earlier

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com